43. Wu Y, Wang T, Ng DYW, Weil T (2012) Multifunctional polypeptide-PEO nanoreactors via
the hydrophobic switch. Macromol Rapid Comm 33:1474–1481. doi:10.1002/marc.
201200227
44. Wu Y, Ihme S, Feuring-Buske M et al (2012) A core-shell albumin copolymer
nanotransporter for high capacity loading and two-step release of doxorubicin with enhanced
anti-leukemia activity. Adv Healthc Mater 2:884–894. doi:10.1002/adhm.201200296
45. Wu Y, Shih EK, Ramanathan A et al (2012) Nano-sized albumin-copolymer micelles for
efficient doxorubicin delivery. Biointerphases 7:5. doi:10.1007/s13758-011-0005-7
46. Eisele K, Gropeanu R, Musante A et al (2010) Tailored albumin-based copolymers for
receptor-mediated delivery of perylenediimide guest molecules. Macromol Rapid Commun
31:1501–1508. doi:10.1002/marc.201000176
47. Zhang H, Vinogradov SV (2010) Short biodegradable polyamines for gene delivery and
transfection of brain capillary endothelial cells. J Control Release 143:359–366. doi:10.1016/
j.jconrel.2010.01.020
48. Zhang H, Mitin A, Vinogradov SV (2009) Efficient transfection of blood–brain barrier
endothelial cells by lipoplexes and polyplexes in the presence of nuclear targeting
NLS-PEG-acridine conjugates. Bioconjug Chem 20:120–128. doi:10.1021/bc8003414
49. Slanina H, Schmutzler M, Christodoulides M et al (2012) Effective plasmid DNA and small
interfering RNA delivery to diseased human brain microvascular endothelial cells. J Mol
Microbiol Biotechnol 22:245–257. doi:10.1159/000342909
50. Chen C, Mei H, Shi W et al (2013) EGFP-EGF1-conjugated PLGA nanoparticles for targeted
delivery of siRNA into injured brain microvascular endothelial cells for efficient RNA
interference. PLoS One 8:e60860. doi:10.1371/journal.pone.0060860
51. McTaggart S, Al-Rubeai M (2002) Retroviral vectors for human gene delivery. Biotechnol
Adv 20:1–31
52. Verma IM, Weitzman MD (2005) Gene therapy: twenty-first century medicine. Annu Rev
Biochem 74:711–738. doi:10.1146/annurev.biochem.74.050304.091637
53. Kay MA, Glorioso JC, Naldini L (2001) Viral vectors for gene therapy: the art of turning
infectious agents into vehicles of therapeutics. Nat Med 7:33–40. doi:10.1038/83324
54. Wong HH, Lemoine NR, Wang Y (2010) Oncolytic viruses for cancer therapy: overcoming
the obstacles. Viruses 2:78–106. doi:10.3390/v2010078
55. Nayak S, Herzog RW (2010) Progress and prospects: immune responses to viral vectors.
Gene Ther 17:295–304. doi:10.1038/gt.2009.148
56. Van den Pol AN, Ozduman K, Wollmann G et al (2009) Viral strategies for studying the
brain, including a replication-restricted self-amplifying delta-G vesicular stomatis virus that
rapidly expresses transgenes in brain and can generate a multicolor golgi-like expression.
J Comp Neurol 516:456–481. doi:10.1002/cne.22131
57. Lim ST, Airavaara M, Harvey BK (2010) Viral vectors for neurotrophic factor delivery: a
gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol Res 61:14–26.
doi:10.1016/j.phrs.2009.10.002
58. Kabanov AV (1999) Taking polycation gene delivery systems from in vitro to in vivo. Pharm
Sci Technolo Today 2:365–372
59. El-Aneed A (2004) An overview of current delivery systems in cancer gene therapy. J Control
Release 94:1–14
60. Thomas M, Klibanov AM (2003) Non-viral gene therapy: polycation-mediated DNA delivery. Appl Microbiol Biotechnol 62:27–34. doi:10.1007/s00253-003-1321-8
61. Ditto AJ, Shah PN, Yun YH (2009) Non-viral gene delivery using nanoparticles. Expert Opin
Drug Deliv 6:1149–1160. doi:10.1517/17425240903241796
62. Conwell CC, Huang L (2005) Recent advances in non-viral gene delivery. Adv Genet
53PA:1–18. doi:10.1016/S0065-2660(05)53001-3
63. Salcher EE, Wagner E (2010) Chemically programmed polymers for targeted DNA and
siRNA transfection. Top Curr Chem 296:227–249
64. Ogris M (2010) Cancer gene therapies come of age. Ther Deliv 1:211–214
Polymer Complexes in Biological Applications
233
the hydrophobic switch. Macromol Rapid Comm 33:1474–1481. doi:10.1002/marc.
201200227
44. Wu Y, Ihme S, Feuring-Buske M et al (2012) A core-shell albumin copolymer
nanotransporter for high capacity loading and two-step release of doxorubicin with enhanced
anti-leukemia activity. Adv Healthc Mater 2:884–894. doi:10.1002/adhm.201200296
45. Wu Y, Shih EK, Ramanathan A et al (2012) Nano-sized albumin-copolymer micelles for
efficient doxorubicin delivery. Biointerphases 7:5. doi:10.1007/s13758-011-0005-7
46. Eisele K, Gropeanu R, Musante A et al (2010) Tailored albumin-based copolymers for
receptor-mediated delivery of perylenediimide guest molecules. Macromol Rapid Commun
31:1501–1508. doi:10.1002/marc.201000176
47. Zhang H, Vinogradov SV (2010) Short biodegradable polyamines for gene delivery and
transfection of brain capillary endothelial cells. J Control Release 143:359–366. doi:10.1016/
j.jconrel.2010.01.020
48. Zhang H, Mitin A, Vinogradov SV (2009) Efficient transfection of blood–brain barrier
endothelial cells by lipoplexes and polyplexes in the presence of nuclear targeting
NLS-PEG-acridine conjugates. Bioconjug Chem 20:120–128. doi:10.1021/bc8003414
49. Slanina H, Schmutzler M, Christodoulides M et al (2012) Effective plasmid DNA and small
interfering RNA delivery to diseased human brain microvascular endothelial cells. J Mol
Microbiol Biotechnol 22:245–257. doi:10.1159/000342909
50. Chen C, Mei H, Shi W et al (2013) EGFP-EGF1-conjugated PLGA nanoparticles for targeted
delivery of siRNA into injured brain microvascular endothelial cells for efficient RNA
interference. PLoS One 8:e60860. doi:10.1371/journal.pone.0060860
51. McTaggart S, Al-Rubeai M (2002) Retroviral vectors for human gene delivery. Biotechnol
Adv 20:1–31
52. Verma IM, Weitzman MD (2005) Gene therapy: twenty-first century medicine. Annu Rev
Biochem 74:711–738. doi:10.1146/annurev.biochem.74.050304.091637
53. Kay MA, Glorioso JC, Naldini L (2001) Viral vectors for gene therapy: the art of turning
infectious agents into vehicles of therapeutics. Nat Med 7:33–40. doi:10.1038/83324
54. Wong HH, Lemoine NR, Wang Y (2010) Oncolytic viruses for cancer therapy: overcoming
the obstacles. Viruses 2:78–106. doi:10.3390/v2010078
55. Nayak S, Herzog RW (2010) Progress and prospects: immune responses to viral vectors.
Gene Ther 17:295–304. doi:10.1038/gt.2009.148
56. Van den Pol AN, Ozduman K, Wollmann G et al (2009) Viral strategies for studying the
brain, including a replication-restricted self-amplifying delta-G vesicular stomatis virus that
rapidly expresses transgenes in brain and can generate a multicolor golgi-like expression.
J Comp Neurol 516:456–481. doi:10.1002/cne.22131
57. Lim ST, Airavaara M, Harvey BK (2010) Viral vectors for neurotrophic factor delivery: a
gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol Res 61:14–26.
doi:10.1016/j.phrs.2009.10.002
58. Kabanov AV (1999) Taking polycation gene delivery systems from in vitro to in vivo. Pharm
Sci Technolo Today 2:365–372
59. El-Aneed A (2004) An overview of current delivery systems in cancer gene therapy. J Control
Release 94:1–14
60. Thomas M, Klibanov AM (2003) Non-viral gene therapy: polycation-mediated DNA delivery. Appl Microbiol Biotechnol 62:27–34. doi:10.1007/s00253-003-1321-8
61. Ditto AJ, Shah PN, Yun YH (2009) Non-viral gene delivery using nanoparticles. Expert Opin
Drug Deliv 6:1149–1160. doi:10.1517/17425240903241796
62. Conwell CC, Huang L (2005) Recent advances in non-viral gene delivery. Adv Genet
53PA:1–18. doi:10.1016/S0065-2660(05)53001-3
63. Salcher EE, Wagner E (2010) Chemically programmed polymers for targeted DNA and
siRNA transfection. Top Curr Chem 296:227–249
64. Ogris M (2010) Cancer gene therapies come of age. Ther Deliv 1:211–214
Polymer Complexes in Biological Applications
233